February 2020

Lessons From the Front: Designing and Implementing Clinical Pathways by and for Clinicians

February 19, 2020

Evidence-Based Oncology

As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.

Clinical Pathways: Reducing Costs and Improving Quality Across a Network

February 19, 2020

Evidence-Based Oncology

As the cost of oncology drugs only continues to rise, incorporating clinical pathways into cancer care helps streamline the integration of evidence-based best practices while improving quality and reducing costs for patients and payers.

From the Editor-in-Chief: The End of the Beginning

February 19, 2020

Evidence-Based Oncology

Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.

Speaking of Employers: Purchasers Detail the Challenges of Getting a Handle on Oncology Care Costs

February 20, 2020

Evidence-Based Oncology

As today’s employers try to balance the need to provide healthcare for their workers while keeping an eye on cost, they are banding together to learn more about cancer care and how to gain value for the millions they are spending. Last fall during the Community Oncology Alliance Payer Exchange Summit, leaders from employer and purchasing groups shared experiences from their members in a roundtable discussion.

Biomarker Testing Can Direct Care, but Only If Clinicians Perform the Right Tests

February 20, 2020

Evidence-Based Oncology

Opportunities for precision medicine can be lost if clinicians do not perform biomarker testing, and payers may be part of the reason, according to Stuart Goldberg, MD, a hematologist/oncologist and chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.

Faster Drug Approvals, Weaker Data? Study Raises Questions About FDA Process

February 21, 2020

Evidence-Based Oncology

Special approval programs have increased FDA administrative costs (paid for mostly by user fees), and postponements of generic competition have been costly to the US healthcare system, according to a recent article in JAMA.